Androxal enclomiphene: Completed Phase III enrollment

Repros completed enrollment of 120 patients in the double-blind, placebo-controlled, U.S. Phase III ZA-305 trial comparing 12.5 or 25 mg oral Androxal vs. AndroGel 1.62% testosterone gel for 16 weeks...